Degarelix, a novel GnRH blocker from Ferring, moves into phase III
inFollowing the presentation today of the results of the Phase IIb programme with degarelix in prostate cancer, which are in line with previous promising studies, Ferring Pharmaceuticals announced the immediate start of Phase III trials…